Table 2 Elevated serum tumour marker levels at diagnosis
From: Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
Markers | Normal range | No. of measured patients | No. of patients with elevated levels (%) |
|---|---|---|---|
AFP | ⩽10 ng ml−1 | 42 | 2 (4.7) |
β-HCG | ⩽0.5 mIU ml−1 | 42 | 22 (52.4) |
Cyfra | ⩽2.2 ng ml−1 | 41 | 30 (73.2) |
SCC | ⩽1.5 ng ml−1 | 41 | 7 (17.1) |
NSE | ⩽15 ng ml−1 | 42 | 10 (23.8) |
ProGRP | <46 pg ml−1 | 41 | 8 (19.5) |
PSA | ⩽2.7 ng ml−1 | 23 | 5 (21.7) |
CEA | ⩽5.0 ng ml−1 | 43 | 19 (44.2) |
SLX | ⩽38 U ml−1 | 41 | 21 (51.2) |
STN | ⩽45 U ml−1 | 41 | 16 (39) |
NCC-ST439 | ⩽4.5 U ml−1 | 41 | 16 (39) |
CA125 | ⩽35 U ml−1 | 39 | 25 (64.1) |
CA15-3 | ⩽28 U ml−1 | 41 | 12 (29.3) |
CA19-9 | ⩽37 U ml−1 | 43 | 17 (39.5) |
PIVKA-II | <40 mIU ml−1 | 39 | 2 (5.1) |
Elastase | ⩽300 ng dl−1 | 41 | 3 (7.3) |
